These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 10068580)

  • 1. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection.
    Davey RT; Chaitt DG; Albert JM; Piscitelli SC; Kovacs JA; Walker RE; Falloon J; Polis MA; Metcalf JA; Masur H; Dewar R; Baseler M; Fyfe G; Giedlin MA; Lane HC
    J Infect Dis; 1999 Apr; 179(4):849-58. PubMed ID: 10068580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
    Losso MH; Belloso WH; Emery S; Benetucci JA; Cahn PE; Lasala MC; Lopardo G; Salomon H; Saracco M; Nelson E; Law MG; Davey RT; Allende MC; Lane HC
    J Infect Dis; 2000 May; 181(5):1614-21. PubMed ID: 10823761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.
    Tambussi G; Ghezzi S; Nozza S; Vallanti G; Magenta L; Guffanti M; Brambilla A; Vicenzi E; Carrera P; Racca S; Soldini L; Gianotti N; Murone M; Veglia F; Poli G; Lazzarin A
    J Infect Dis; 2001 May; 183(10):1476-84. PubMed ID: 11319683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons.
    Davey RT; Chaitt DG; Piscitelli SC; Wells M; Kovacs JA; Walker RE; Falloon J; Polis MA; Metcalf JA; Masur H; Fyfe G; Lane HC
    J Infect Dis; 1997 Apr; 175(4):781-9. PubMed ID: 9086130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients.
    Herzmann C; Cuthbertson Z; Fosdick L; Fisher M; Nelson M; Perry N; Law M; Wand H; Janossy G; Johnson MA; Youle M
    J Antimicrob Chemother; 2008 Sep; 62(3):583-6. PubMed ID: 18587135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
    Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
    Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with Arnó A; Ruiz L; Juan M; Jou A; Balagué M; Zayat MK; Marfil S; Martínez-Picado J; Martínez MA; Romeu J; Pujol-Borrell R; Lane C; Clotet B
    J Infect Dis; 1999 Jul; 180(1):56-60. PubMed ID: 10353861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.
    Eton O; Rosenblum MG; Legha SS; Zhang W; Jo East M; Bedikian A; Papadopoulos N; Buzaid A; Benjamin RS
    Cancer; 2002 Jul; 95(1):127-34. PubMed ID: 12115326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity.
    Meropol NJ; Porter M; Blumenson LE; Lindemann MJ; Perez RP; Vaickus L; Loewen GM; Creaven PJ; Wilkes KA; Giedlin MA; Caligiuri MA
    Clin Cancer Res; 1996 Apr; 2(4):669-77. PubMed ID: 9816217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nadir CD4+ T cell count predicts response to subcutaneous recombinant interleukin-2.
    Markowitz N; Bebchuk JD; Abrams DI;
    Clin Infect Dis; 2003 Oct; 37(8):e115-20. PubMed ID: 14523786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase-II study.
    Lissoni P; Vigorè L; Rescaldani R; Rovelli F; Brivio F; Giani L; Barni S; Tancini G; Ardizzoia A; Viganò MG
    J Biol Regul Homeost Agents; 1995; 9(4):155-8. PubMed ID: 8844341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
    Romano F; Piacentini MG; Franciosi C; Caprotti R; De Fina S; Cesana G; Uggeri F; Conti M; Uggeri F
    Hepatogastroenterology; 2004; 51(60):1872-6. PubMed ID: 15532847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment.
    David D; Naït-Ighil L; Dupont B; Maral J; Gachot B; Thèze J
    J Infect Dis; 2001 Mar; 183(5):730-5. PubMed ID: 11181149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy.
    Hirsch M; Steigbigel R; Staszewski S; Mellors J; Scerpella E; Hirschel B; Lange J; Squires K; Rawlins S; Meibohm A; Leavitt R
    J Infect Dis; 1999 Sep; 180(3):659-65. PubMed ID: 10438352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1B study of subcutaneously administered interleukin 2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer.
    Recchia F; De Filippis S; Rosselli M; Saggio G; Cesta A; Fumagalli L; Rea S
    Clin Cancer Res; 2001 May; 7(5):1251-7. PubMed ID: 11350891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.
    Marchetti G; Meroni L; Varchetta S; Terzieva V; Bandera A; Manganaro D; Molteni C; Trabattoni D; Fossati S; Clerici M; Galli M; Moroni M; Franzetti F; Gori A
    J Infect Dis; 2002 Sep; 186(5):606-16. PubMed ID: 12195347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansion.
    Miller KD; Spooner K; Herpin BR; Rock-Kress D; Metcalf JA; Davey RT; Falloon J; Kovacs JA; Polis MA; Walker RE; Masur H; Lane HC
    Clin Immunol; 2001 Apr; 99(1):30-42. PubMed ID: 11286539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.
    Tavel JA; Sereti I; Walker RE; Hahn B; Kovacs JA; Jagannatha S; Davey RT; Falloon J; Polis MA; Masur H; Metcalf JA; Stevens R; Rupert A; Baseler M; Lane HC
    J Infect Dis; 2003 Aug; 188(4):531-6. PubMed ID: 12898439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between virus load response to highly active antiretroviral therapy and change in CD4 cell counts: A report from the Women's interagency HIV study.
    DeHovitz JA; Kovacs A; Feldman JG; Anastos K; Young M; Cohen M; Gange SJ; Melnick S; Greenblatt RM
    J Infect Dis; 2000 Nov; 182(5):1527-30. PubMed ID: 11010840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
    Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
    Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.